Cassava Sciences Alzheimer’s Drug Fails, Stocks Plunge
25 Nov 2024 21:32 PM IST
Cassava Sciences Inc. faced a major setback as its Alzheimer's drug, simufilam, failed to meet critical endpoints in a Phase 3 trial, causing the company's stock to plunge by over 84%. The disappointing results also led to the discontinuation of ongoing studies and cast further scrutiny on the biotech firm's controversial history.